Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
life sciences
national blog main
san francisco
3
×
san francisco blog main
san francisco top stories
startups
3
×
boston top stories
deals
investing
national top stories
acetylon pharmaceuticals
alphabet
ambys medicines
ame cloud ventures
american diabetes association
broad institute of harvard and mit
brook byers
cell therapy
charles chu
clinical trials
clostridium difficile
colleen cutcliffe
computational biology
constellation pharmaceuticals
crispr
crispr cas14
decheng capital
diabetes type 2
diagnostic
fda
gene therapy
genentech
google
holger willenbring
infectious disease
inflammatory bowel disease
ipo
jeffrey tong
What
today
3
×
available
big
launch
treatments
aiming
ambys
balance
based
bio
biome
biosciences
biotech
blood
cas
cheaper
control
crispr
deadly
deal
debuted
develop
diabetes
diagnostics
diseases
expects
eyes
faster
food
formed
future
healthy
hormone
include
intended
leads
levels
liver
make
mammoth
Language
unset
Current search:
today
×
startups
×
" san francisco "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?